SCHEMBL1407669

SCHEMBL1407669

Fc1ccc(C(F)n2nc3c(C(F)(F)F)cccc3c2-c2cccc(N3CCC4(CC3)OCCO4)c2)c(F)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.35
HPGD P15428 3/20 0.35
MAPT P10636 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35
KDM4E B2RXH2 2/20 0.35
LMNA P02545 2/20 0.35
GAA P10253 2/20 0.35
TDP1 Q9NUW8 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
MAPK1 P28482 1/20 0.35
RCE1 Q9Y256 1/20 0.35
NR1H2 P55055 9/20 0.35
NR1H3 Q13133 9/20 0.35
NR1I2 O75469 2/20 0.35
NR3C1 P04150 2/20 0.35
AR P10275 1/20 0.35
RXRA P19793 1/20 0.35
USP2 O75604 1/20 0.34
TSHR P16473 1/20 0.34
HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3861597 0.80 NR1H2 (0.46) ALDH1A1HPGDMAPTNPSR1KDM4E
SCHEMBL1407814 0.72 NR1H2 (0.51) ALDH1A1HPGDMAPTNPSR1KDM4E
SCHEMBL1407440 0.71 NR1H2 (0.45) ALDH1A1LMNAMAPK1NR1H2NR1H3
SCHEMBL5244461 0.70 ITGB2 (0.40) NR1H2NR1H3NR1I2NR3C1SOS1
SCHEMBL31067148 0.66 SLC6A2 (0.50) ALDH1A1HPGDMAPTNPSR1KDM4E
SCHEMBL1407879 0.65 NR1H2 (0.54) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL27730583 0.64 NR1H2 (0.47) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1407980 0.64 NR1H2 (0.48) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1407366 0.64 NR1H2 (0.50) ALDH1A1LMNANR1H2NR1H3NR1I2
SCHEMBL3857590 0.64 NR1H2 (0.44) ALDH1A1NR1H2NR1H3NR1I2NR3C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2295429-A1 3-((hetero)aryl)-indazoles as Liver X receptor (LXR) and Th-1 inhibitors for the treatment of cardiovascular diseases Wyeth LLC (US) 2011-03-16 EP disclosed